<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004809</url>
  </required_header>
  <id_info>
    <org_study_id>199/12011</org_study_id>
    <secondary_id>UPHS-28040</secondary_id>
    <nct_id>NCT00004809</nct_id>
  </id_info>
  <brief_title>Phase I Study of Ex Vivo Liver-Directed Gene Therapy for Familial Hypercholesterolemia</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Center for Research Resources (NCRR)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Office of Rare Diseases (ORD)</source>
  <brief_summary>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. Develop an approach for treating patients with homozygous familial hypercholesterolemia&#xD;
      using gene therapy with autologous hepatocytes transduced with a normal low-density&#xD;
      lipoprotein receptor gene.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROTOCOL OUTLINE: Autologous hepatocytes are obtained from a partial hepatectomy and&#xD;
      transduced with a recombinant retroviral vector containing the low-density lipoprotein&#xD;
      receptor gene. The transduced hepatocytes are infused via the inferior mesenteric vein 3 days&#xD;
      following surgery.&#xD;
&#xD;
      Traditional therapy is discontinued for 4 weeks prior to protocol therapy and may resume 6&#xD;
      weeks after the hepatocyte infusion.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 1992</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>5</enrollment>
  <condition>Familial Hypercholesterolemia</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>gene therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PROTOCOL ENTRY CRITERIA:&#xD;
&#xD;
        --Disease Characteristics-- Homozygous familial hypercholesterolemia, i.e.: Low-density&#xD;
        lipoprotein (LDL) cholesterol greater than 500 mg/dL Autosomal dominant inheritance&#xD;
        Early-onset tendon and tuberous xanthomas LDL receptor negative, i.e.: Receptor binding in&#xD;
        cultured fibroblasts no more than 20% of normal OR Genotype with 2 previously described,&#xD;
        disease-causing alleles Advanced coronary heart disease with relatively poor prognosis,&#xD;
        i.e: Angina pectoris History of myocardial infarction Positive exercise tolerance test&#xD;
        Atherosclerotic disease in proximal aorta or coronary arteries by ultrasound or angiogram&#xD;
        None of the following: Unstable angina pectoris Left ventricular ejection fraction less&#xD;
        than 30% Decompensated congestive heart failure Untreated ventricular tachycardia Moderate&#xD;
        to severe aortic stenosis Other dyslipidemia Obstructive hepatobiliary disease&#xD;
&#xD;
          -  Prior/Concurrent Therapy At least 2 weeks since the following: Drugs affecting&#xD;
             cholesterol metabolism Plasma exchange LDL apheresis --Patient Characteristics-- Age:&#xD;
             Any age Renal: No azotemia No significant proteinuria Other: No hypothyroidism No&#xD;
             diabetes&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>0 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James M. Wilson</last_name>
    <role>Study Chair</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <verification_date>December 2001</verification_date>
  <study_first_submitted>February 24, 2000</study_first_submitted>
  <study_first_submitted_qc>February 24, 2000</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2000</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>familial hypercholesterolemia</keyword>
  <keyword>inborn errors of metabolism</keyword>
  <keyword>rare disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipoproteinemia Type II</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

